Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Slides:

Advertisements

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Advertisements

Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

In vivo function of MeTro sealants using rat incision model of lungs

Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 3. BET inhibition reduces homologous recombination.

Fig. 3 BX795 blocks the synthesis of HSV-1 virions.

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 5 A competent Fc is required for the antitumor immune response.

FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.

Fig. 2 Systemically released inflammatory factors directly affect HSC-e cell fate. Systemically released inflammatory factors directly affect HSC-e cell.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4 CXCL4 potentiates TLR8-mediated activation of SSc pDCs.

Fig. 3 Biological function of TG2 and the interaction with MT-2.

Fig. 5. Remnants of PS+ platelets induce neutrophil macroaggregation.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 4. MATE1 transcription in RCC.

Fig. 7 pDCs are critical for the maintenance of skin fibrosis and for the presence of CXCL4 in the skin. pDCs are critical for the maintenance of skin.

Fig. 8 TLR8 exacerbates disease in the BLM-induced fibrosis model.

Fig. 6 pDCs infiltrate the skin of BLM-treated mice, and their depletion attenuates skin fibrosis. pDCs infiltrate the skin of BLM-treated mice, and their.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

AG-221 can reduce intracellular 2HG levels and induce differentiation in primary human IDH2R140Q- or IDH2R172K-mutant AML patient samples treated ex vivo.

Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target

Fig. 2 Paralog-selective inhibitors of GSK3α and GSK3β were designed and characterized. Paralog-selective inhibitors of GSK3α and GSK3β were designed and.

Fig. 5 CXCL4 potentiates TLR9-mediated activation but has minimal effect on TLR7-mediated activation of pDCs purified from SSc or HDs. CXCL4 potentiates.

Fig. 7. Inhibitory mechanisms of C12G6.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 7 DMN-Tre labeling of Mycobacterium tuberculosis is inhibited by tuberculosis drug cocktail, unlike auramine staining. DMN-Tre labeling of Mycobacterium.

Fig. 4 PD-L1 expression is found in the spleen and the BM of mice transplanted with JAK2V617F-transduced bone marrow. PD-L1 expression is found in the.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 1 Effect of preinfection β7Hi CD45RA−CD4+ T cell frequency on HIV acquisition risk in CAPRISA 004 study. Effect of preinfection β7Hi CD45RA−CD4+ T.

PAAND is driven by local inflammasome activation and IL-1β production

Fig. 3. HECTD2 contains a naturally occurring polymorphism at A19, which mislocalizes to the cytosol. HECTD2 contains a naturally occurring polymorphism.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 4 Spinally grafted iPSC-NPCs show long-term survival and neuronal and glial differentiation in syngeneic recipient in the absence of immunosuppression.

Vaccination induces activation of cTFH cells and transient ASCs

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Fig. 5 Metarrestin treatment induces nucleolar structure changes.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 6 Combination therapy with LVSOD2 and LVshCTGF preserves flap volume and reduces fibrosis after RT. Combination therapy with LVSOD2 and LVshCTGF preserves.

Fig. 4 ALRN-6924 inhibits cellular proliferation and clonogenic capacity, and induces cell cycle arrest and apoptosis in AML cell lines. ALRN-6924 inhibits.

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Fig. 3. Inactivation of the Wnt/β-catenin signaling pathway inhibited cell proliferation and induced apoptosis in A549 and SPC-A-1 cells. Inactivation.

FGF/ERK inhibition accelerates neural fate conversion of EpiSCs.

Effect of Z-FA-FMK on the expression of SMN proteins in SMA patient iPSCs and iPSC-derived motor neurons. Effect of Z-FA-FMK on the expression of SMN proteins.

Identification of Z-FA-FMK as a potent compound that increases SMN protein expression in HEK293 and patient fibroblast cells. Identification of Z-FA-FMK.

An inhibitor of HSP90β reduces the level of HNF4A protein in hepatic progenitor cells. An inhibitor of HSP90β reduces the level of HNF4A protein in hepatic.

HGF recruits additional synapsin 1 to MET receptor complex.

Fig. 2 Paralog-selective inhibitors of GSK3α and GSK3β were designed and characterized. Paralog-selective inhibitors of GSK3α and GSK3β were designed and.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Fig. 1 Genes up-regulated in Zic5 KO cells correlate with the increased glycolytic state. Genes up-regulated in Zic5 KO cells correlate with the increased.

miR can promote cardiomyocyte proliferation in the adult heart

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

Presentation transcript:

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. (A and B) Time-response (A) and dose-response (B) Western immunoblots for β-catenin, phospho-GSK3α/β (Tyr279/216), total GSK3α/β, glycogen synthase (GYS), phospho-GYS (S641), and vinculin after treatment with the indicated inhibitors in U937 cells. (C) Dose-response Western immunoblot for β-catenin, phospho-GSK3α/β (Tyr279/216), total GSK3α/β, and vinculin after treatment with the indicated inhibitors in primary AML patient samples. (D) May-Grunwald-Giemsa staining after BRD0705 treatment for 6 days. Scale bar, 10 μm. (E) Fluorescence-activated cell sorting (FACS) analysis of the expression of CD11b, CD11c, and CD14 cell surface markers after BRD0705 treatment. *P < 0.05 calculated using a Welch’s t test in comparison with the control condition. Data are means ± SEM of three replicates. (F) FACS analysis of the expression of CD14 and CD117 cell surface markers in five primary AML samples treated with BRD0705. *P < 0.05 calculated using nonparametric Mann-Whitney test in comparison with control condition. Data are means ± SEM of five primary AML samples. (G) Western immunoblot for total GSK3α/β and vinculin in U937 after GSK3α CRISPR KO. (H) FACS analysis of the expression of CD11b cell surface marker in U937 GSK3α-WT, GSK3α-KO#1, and GSK3α-KO#2 treated with the indicated inhibitor. P < 0.05 calculated using a Welch’s t test in comparison with the DMSO condition for each clone (#) or the DMSO condition in the GSK3α-WT clone (*). Data are means ± SEM of three replicates. Florence F. Wagner et al., Sci Transl Med 2018;10:eaam8460 Published by AAAS